Navigation

Heart failure (chronic) - ivabradine [ID484]

Ivabradine for the treatment of chronic heart failure

Status: History
Expected date of issue: November 2012
Referral date: September 2011
Process: STA
Notes:

Scoped within Batch 19

Topic area:
  • Cardiovascular
 

NICE project team

Executive Lead: TBC
Technical Lead: Nwamaka Umeweni
Communications manager: Phillip Ranson
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 30 March 2012
1st appraisal committee meeting: 11 July 2012
2nd appraisal committee meeting 11 September 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Servier Laboratories (ivabradine)

Patient/carer groups

  • South Asian Health Foundation
  • The Patients Association

Professional groups

  • British Association for Nursing in Cardiac Care
  • British Cardiovascular Society
  • British Heart Foundation
  • British Society for Heart Failure
  • Royal College of Nursing
  • Royal College of Physicians

Others

  • Department of Health
  • NHS Devon
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Health Care Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Possible comparator manufacturers

  • Abbott Healthcare Products (eprosartan) (not participating)
  • Actavis UK (spironolactone, losartan, hydralazine, isosorbide dinitrate, valsartan) (Confidentiality agreement not signed, not participating)
  • Amdipharm (hydralazine, losartan) (Confidentiality agreement not signed, not participating)
  • Arrow Generics (losartan) (Confidentiality agreement not signed, not participating)
  • Boehringer Ingelheim (telmisartan) (Confidentiality agreement not signed, not participating)
  • Bristol-Myers Squibb (irbesartan) (not participating)
  • Consilient Health (losartan, valsartan) (Confidentiality agreement not signed, not participating)
  • Daiichi Sankyo UK (olmesartan medoxomil) (Confidentiality agreement not signed, not participating)
  • Dexcel Pharma (losartan. isosorbide dinitrate, valsartan) (Confidentiality agreement not signed, not participating)
  • Dr Reddy’s Laboratories (spironolactone, losartan) (Confidentiality agreement not signed, not participating)
  • Goldshield Critical Care (isosorbide dinitrate) (Confidentiality agreement not signed, not participating)
  • Kent Pharmaceuticals (spironolactone, losartan) (Confidentiality agreement not signed, not participating)
  • Merck Sharp & Dohme (losartan)  (not participating)
  • Metwest Pharmaceuticals (spironolactone) (Confidentiality agreement not signed, not participating)
  • Mylan (losartan, hydralazine, isosorbide dinitrate) (Confidentiality agreement not signed, not participating)
  • Novartis Pharmaceuticals (valsartan) (Confidentiality agreement not signed, not participating)
  • Pfizer (losartan, eplerenone, spironolactone, isosorbide dinitrate)
  • Ranbaxy UK (losartan) (Confidentiality agreement not signed, not participating)
  • Sandoz UK (losartan, isosorbide dinitrate) (Confidentiality agreement not signed, not participating)
  • sanofi (spironolactone, irbesartan) (Confidentiality agreement not signed, not participating)
  • Takeda UK (candesartan cilexetil) (Confidentiality agreement not signed, not participating)
  • Teva UK (spironolactone, losartan, isosorbide dinitrate, valsartan) (Confidentiality agreement not signed, not participating)
  • UCB Pharma (isosorbide dinitrate) (Confidentiality agreement not signed, not participating)
  • Zentiva (losartan, valsartan) (Confidentiality agreement not signed, not participating)

Evidence Review Group

  • BMJ Evidence Centre
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Clinical Guidelines Centre

Top


 

Key documents

This page was last updated: 19 July 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.